神经分泌生物科学(NBIX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NBIX 神经分泌生物科学

交易中 03-18 13:27:53 EDT

130.67

-0.04

-0.03%

最高130.90	最低129.01	成交量25.17万
今开130.43	昨收130.71	日振幅1.45%
总市值131.14亿	流通市值128.06亿	总股本1.00亿
成交额3,273万	换手率0.26%	流通股本9,800万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NBIX","market":"US","secType":"STK","nameCN":"神经分泌生物科学","latestPrice":130.67,"timestamp":1773854866766,"preClose":130.71,"halted":0,"volume":251739,"delay":0,"changeRate":-0.0003060209624360834,"floatShares":98002579,"shares":100363463,"eps":4.67,"marketStatus":"交易中","change":-0.04,"latestTime":"03-18 13:27:53 EDT","open":130.425,"high":130.9,"low":129.01,"amount":32731973.27955,"amplitude":0.014459,"askPrice":130.7,"askSize":5,"bidPrice":130.59,"bidSize":211,"shortable":3,"etf":0,"ttmEps":4.67,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1773864000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":832824000000,"exchange":"NASDAQ","adjPreClose":130.71,"preHourTrading":{"tag":"盘前","latestPrice":131.9,"preClose":130.71,"latestTime":"08:00 EDT","volume":85,"amount":11139.18285,"timestamp":1773835215824,"change":1.19,"changeRate":0.009104,"amplitude":0.010634},"postHourTrading":{"tag":"盘后","latestPrice":130.71,"preClose":130.71,"latestTime":"18:41 EDT","volume":32870,"amount":4296429.46,"timestamp":1773787264254,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.506846,"impliedVol":0.2949,"impliedVolPercentile":0.2032},"requestUrl":"/m/hq/s/NBIX","defaultTab":"news","newsList":[{"id":"1112349305","title":"财报前瞻｜神经分泌生物科学营收预计同比增26.35%，机构观点偏乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1112349305","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112349305?lang=zh_cn&edition=full","pubTime":"2026-02-04 10:23","pubTimestamp":1770171820,"startTime":"0","endTime":"0","summary":"神经分泌生物科学将于2026年02月11日发布财报，市场关注盈利能力与核心产品动能的延续情况。市场一致预期本季度神经分泌生物科学营收约为7.95亿美元，同比增26.35%；调整后每股收益约为1.91美元，同比增22.25%；息税前利润约为2.28亿美元，同比增13.04%。上一季度神经分泌生物科学营收7.95亿美元，同比增长27.78%；毛利率66.79%；归属于母公司净利润2.10亿美元，同比环比增长属性以工具数据为准，净利率26.36%；调整后每股收益2.04美元，同比增长64.52%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜神经分泌生物科学营收预计同比增26.35%，机构观点偏乐观","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBIX"],"gpt_icon":0},{"id":"1149008441","title":"神经分泌生物科学启动评估NBI-1065890治疗成人迟发性运动障碍的二期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1149008441","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149008441?lang=zh_cn&edition=full","pubTime":"2026-01-26 21:33","pubTimestamp":1769434400,"startTime":"0","endTime":"0","summary":"神经分泌生物科学公司已正式启动一项二期临床试验，旨在评估其研究性药物NBI-1065890在成人迟发性运动障碍患者中的疗效与安全性。这项研究的启动标志着公司在推进其神经系统疾病治疗产品管线方面迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBIX","LU2065169927.USD","LU0154245673.USD","LU0320765992.SGD","LU0823416689.USD","LU2065170008.USD","LU0889565916.HKD","BK4139","LU0109394709.USD","LU2065171311.SGD","LU2324357040.USD","LU2065171402.SGD","LU0154245756.USD"],"gpt_icon":0},{"id":"2594229334","title":"DCP 三期研究未达预期 德银重申神经分泌生物科学(NBIX.US)“持有”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2594229334","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594229334?lang=zh_cn&edition=full","pubTime":"2025-12-26 18:35","pubTimestamp":1766745332,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，在神经分泌生物科学公布了未达预期的 DCP 三期研究结果后，德银重申其“持有”评级，并维持152美元目标价。该行认为，投资者对此次临床结果的预期较低，预计股价受到的影响将微乎其微。鉴于DCP适应症的Ingrezza并未纳入德银的估值模型，此适应症的失败不会改变对该公司的估值。在缺乏标签扩展的情况下，德银预计管理层将重点推动Ingrezza处方量的增长，这得到了销售团队扩大的支持，而TD市场预计将增长但目前渗透率不足。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386069.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["NBIX","DCP"],"gpt_icon":0},{"id":"1112720632","title":"神经分泌生物科学：不良事件与瓦尔贝那新已建立的安全性特征大致一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1112720632","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112720632?lang=zh_cn&edition=full","pubTime":"2025-12-23 05:08","pubTimestamp":1766437718,"startTime":"0","endTime":"0","summary":"神经分泌生物科学：不良事件与瓦尔贝那新已建立的安全性特征大致一致","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065169927.USD","LU0823416689.USD","LU0154245756.USD","LU2065171402.SGD","NBIX","LU2324357040.USD","LU2065171311.SGD","LU0154245673.USD","LU0889565916.HKD","LU2065170008.USD","LU0320765992.SGD","BK4139","LU0109394709.USD"],"gpt_icon":0},{"id":"1111020142","title":"神经分泌生物科学：第三阶段Kinect Dcp研究评估Valbenazine的有效性和安全性未达到主要或关键次要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1111020142","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111020142?lang=zh_cn&edition=full","pubTime":"2025-12-23 05:07","pubTimestamp":1766437664,"startTime":"0","endTime":"0","summary":"神经分泌生物科学：第三阶段Kinect Dcp研究评估Valbenazine的有效性和安全性未达到主要或关键次要终点","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065170008.USD","NBIX","LU2065171402.SGD","LU2065169927.USD","LU2065171311.SGD","LU0154245756.USD","BK4139","LU0154245673.USD","LU0823416689.USD","LU0109394709.USD","LU0320765992.SGD","LU2324357040.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"1117004014","title":"神经分泌生物科学公布关于FDA批准的Vmat2抑制剂的具有里程碑意义的叙述性评审，展示Ingrezza®（Valbenazine）胶囊的独特特性","url":"https://stock-news.laohu8.com/highlight/detail?id=1117004014","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117004014?lang=zh_cn&edition=full","pubTime":"2025-11-20 21:31","pubTimestamp":1763645483,"startTime":"0","endTime":"0","summary":"神经分泌生物科学公布关于FDA批准的Vmat2抑制剂的具有里程碑意义的叙述性评审，展示Ingrezza®（Valbenazine）胶囊的独特特性","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","LU0154245673.USD","LU2324357040.USD","LU2065171402.SGD","LU0154245756.USD","LU0889565916.HKD","LU2065170008.USD","NBIX","LU0320765992.SGD","BK4139","LU0109394709.USD","LU2065171311.SGD","LU2065169927.USD"],"gpt_icon":0},{"id":"2510898521","title":"神经分泌生物科学盘中异动 股价大跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510898521","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510898521?lang=zh_cn&edition=full","pubTime":"2025-02-11 01:25","pubTimestamp":1739208314,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日01时25分，神经分泌生物科学股票出现异动，股价快速跳水5.01%。截至发稿，该股报116.48美元/股，成交量119.903万股，换手率1.18%，振幅7.49%。神经分泌生物科学股票所在的制药行业中，整体跌幅为0.65%。神经分泌生物科学公司简介：Neurocrine Biosciences Inc 是一家研究型制药公司。该公司推动中枢神经系统和内分泌相关类别的候选药物的发展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211012514abc9caca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211012514abc9caca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0889565916.HKD","BK4139","LU0823416689.USD","LU2065171311.SGD","LU2065169927.USD","NBIX","LU0320765992.SGD","LU2065170008.USD","LU2065171402.SGD","LU0109394709.USD","LU2324357040.USD"],"gpt_icon":0},{"id":"2510688998","title":"Guggenheim：维持Neurocrine Biosciences(NBIX.US)评级，由买入调整至买入评级, 目标价由165.00美元调整至163.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2510688998","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510688998?lang=zh_cn&edition=full","pubTime":"2025-02-10 22:01","pubTimestamp":1739196109,"startTime":"0","endTime":"0","summary":"Guggenheim：维持Neurocrine Biosciences(NBIX.US)评级，由买入调整至买入评级, 目标价由165.00美元调整至163.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/10220148063374.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["NBIX"],"gpt_icon":0},{"id":"2510472180","title":"神经分泌生物科学2024财年实现净利润3.41亿美元，同比增加36.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510472180","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510472180?lang=zh_cn&edition=full","pubTime":"2025-02-10 00:01","pubTimestamp":1739116869,"startTime":"0","endTime":"0","summary":"2月10日，神经分泌生物科学公布财报，公告显示公司2024财年净利润为3.41亿美元，同比增加36.40%；其中营业收入为23.55亿美元，同比增加24.80%，每股基本收益为3.40美元。从资产负债表来看，神经分泌生物科学总负债11.29亿美元，其中短期债务0.00美元，资产负债比为3.30，流动比率为3.40。机构评级：截至2025年2月10日，当前有23家机构对神经分泌生物科学目标价做出预测，其中目标均价为169.78美元，其中最低目标价为140.00美元，最高目标价为192.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210000149a23f5e13&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210000149a23f5e13&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NBIX"],"gpt_icon":0},{"id":"2509776513","title":"加拿大皇家银行：维持Neurocrine Biosciences(NBIX.US)评级，由与大盘持平调整至与大盘持平评级, 目标价由154.00美元调整至148.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2509776513","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509776513?lang=zh_cn&edition=full","pubTime":"2025-02-08 04:23","pubTimestamp":1738959781,"startTime":"0","endTime":"0","summary":"加拿大皇家银行：维持Neurocrine Biosciences(NBIX.US)评级，由与大盘持平调整至与大盘持平评级, 目标价由154.00美元调整至148.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/08042348031835.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["NBIX"],"gpt_icon":0},{"id":"2509778265","title":"Wedbush：维持Neurocrine Biosciences(NBIX.US)评级，由优于大市调整至优于大市评级, 目标价由157.00美元调整至147.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2509778265","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509778265?lang=zh_cn&edition=full","pubTime":"2025-02-08 03:11","pubTimestamp":1738955504,"startTime":"0","endTime":"0","summary":"Wedbush：维持Neurocrine Biosciences(NBIX.US)评级，由优于大市调整至优于大市评级, 目标价由157.00美元调整至147.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/08031148031719.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["NBIX"],"gpt_icon":0},{"id":"2509877826","title":"加拿大投资银行集团：维持Neurocrine Biosciences(NBIX.US)评级，由买入调整至买入评级, 目标价由172.00美元调整至163.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2509877826","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509877826?lang=zh_cn&edition=full","pubTime":"2025-02-08 03:04","pubTimestamp":1738955052,"startTime":"0","endTime":"0","summary":"加拿大投资银行集团：维持Neurocrine Biosciences(NBIX.US)评级，由买入调整至买入评级, 目标价由172.00美元调整至163.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/08030448031701.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["NBIX"],"gpt_icon":0},{"id":"1100166828","title":"异动解读 | 神经分泌生物科学(NBIX)盘中大跌16.28%,分析师下调评级导致前景担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1100166828","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100166828?lang=zh_cn&edition=full","pubTime":"2025-02-07 22:34","pubTimestamp":1738938881,"startTime":"0","endTime":"0","summary":"今日,神经分泌生物科学(NBIX)盘中股价暴跌16.28%,引发了投资者广泛关注。\n\n导致该股大幅下跌的主要原因是,多家分析机构在最新研究报告中下调了对NBIX的评级和目标价。其中,Canaccord Genuity将NBIX目标价从172美元大幅下调至163美元;而B of A Securities虽然维持该股\"买入\"评级,但也将目标价从184美元下调至179美元。\n\n分析师纷纷下调评级和目标价,反映出他们对NBIX未来增长前景的担忧。这令投资者对公司长期发展产生怀疑,从而在盘中抛售该股,造成股价大幅下跌。不过,具体导致分析师下调的原因还有待进一步解释和分析。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NBIX"],"gpt_icon":0},{"id":"2509744291","title":"神经分泌生物科学盘中异动 急速下跌14.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509744291","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509744291?lang=zh_cn&edition=full","pubTime":"2025-02-07 22:31","pubTimestamp":1738938712,"startTime":"0","endTime":"0","summary":"北京时间2025年02月07日22时31分，神经分泌生物科学股票出现异动，股价大幅下跌14.63%。截至发稿，该股报128.50美元/股，成交量22.3269万股，换手率0.22%，振幅1.77%。神经分泌生物科学股票所在的制药行业中，整体涨幅为0.28%。该公司推动中枢神经系统和内分泌相关类别的候选药物的发展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207223152a23d2345&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207223152a23d2345&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NBIX","LU0109394709.USD","LU2065171311.SGD","LU2324357040.USD","BK4139","LU0889565916.HKD","LU2065170008.USD","LU2065171402.SGD","LU0823416689.USD","LU0320765992.SGD","LU2065169927.USD"],"gpt_icon":0},{"id":"1174737035","title":"异动解读 | 神经分泌生物科学(NBIX)盘前大跌16.2%,分析师调低目标价令投资者忧虑前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1174737035","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174737035?lang=zh_cn&edition=full","pubTime":"2025-02-07 22:30","pubTimestamp":1738938626,"startTime":"0","endTime":"0","summary":"神经分泌生物科学公司(NBIX)在本周五(2月7日)盘前大跌16.2%,引发市场对该公司前景的广泛忧虑。\n\n导致该股大幅下跌的主要原因是,多家分析师在最新的研究报告中下调了对NBIX的评级和目标价。其中,Canaccord Genuity将NBIX的目标价从172美元下调至163美元;此外,B of A Securities维持该股\"买入\"评级,但也将目标价从184美元下调至179美元。\n\n分析师减持或下调目标价,令投资者对NBIX的长期增长前景产生质疑和担忧,从而在盘前交易中抛售该股票,导致大幅下跌。不过,具体原因还有待进一步了解和分析。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | 神经分泌生物科学(NBIX)盘前大跌16.2%,分析师调低目标价令投资者忧虑前景","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NBIX"],"gpt_icon":0},{"id":"2509105057","title":"B of A Securities：维持Neurocrine Biosciences(NBIX.US)评级，由买入调整至买入评级, 目标价由184.00美元调整至179.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2509105057","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509105057?lang=zh_cn&edition=full","pubTime":"2025-02-07 20:22","pubTimestamp":1738930975,"startTime":"0","endTime":"0","summary":"B of A Securities：维持Neurocrine Biosciences(NBIX.US)评级，由买入调整至买入评级, 目标价由184.00美元调整至179.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/07202248026914.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["NBIX"],"gpt_icon":0},{"id":"1104699112","title":"异动解读 | 神经分泌生物科学股价盘后重挫10.64%,2024年Q4营收增长超预期但盈利未达预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1104699112","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104699112?lang=zh_cn&edition=full","pubTime":"2025-02-07 06:04","pubTimestamp":1738879494,"startTime":"0","endTime":"0","summary":"神经分泌生物科学公司(NBIX)今日盘后股价大跌10.64%,引发了市场的广泛关注。根据新闻报道,这一大跌可能与公司2024年第四季度财报表现有关:\n\n公司本季度营收为6.277亿美元,同比增长21.8%,高于市场预期。但每股收益为1.69美元,虽然同比增长9.74%,却低于分析师预期的1.71美元。\n\n分析人士认为,尽管神经分泌生物科学的营收表现出色,但未能达到盈利预期可能是导致股价大跌的主要原因。投资者对公司的盈利能力表示担忧,因此在盘后出现大幅抛售。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NBIX"],"gpt_icon":0},{"id":"1109521163","title":"Neurocrine生物科学公司2024年第四季度每股收益为$1.69，超过预期的$1.56，销售额为$6.277亿，未达预期的$6.2899亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1109521163","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109521163?lang=zh_cn&edition=full","pubTime":"2025-02-07 05:14","pubTimestamp":1738876473,"startTime":"0","endTime":"0","summary":"Neurocrine生物科学公司报告季度每股收益为$1.69，超过分析师一致预期的$1.56，超出8.33%。该公司报告季度销售额为$6.277亿，未达到分析师一致预期的$6.2899亿，差距为0.20%。与去年同期销售额$5.152亿相比增长了21.84%。以上内容来自Benzinga Earnings专栏，原文如下：Neurocrine Biosciences  reported quarterly earnings of $1.69 per share which beat the analyst consensus estimate of $1.56 by 8.33 percent. This is a 9.74 percent increase over earnings of $1.54 per share from the same period last year.  The company reported quarterly sales of $627.70 million which missed the analyst consensus estimate of","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Neurocrine生物科学公司2024年第四季度每股收益为$1.69，超过预期的$1.56，销售额为$6.277亿，未达预期的$6.2899亿","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBIX"],"gpt_icon":0},{"id":"2509781914","title":"Neurocrine Biosciences(NBIX.US)：2024年Q4财报实现营收6.277亿美元，前值为5.152亿美元，预期值为6.29亿美元；每股收益为1.69美元，前值为1.54美元，预期值为1.71美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2509781914","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509781914?lang=zh_cn&edition=full","pubTime":"2025-02-07 05:12","pubTimestamp":1738876320,"startTime":"0","endTime":"0","summary":"Neurocrine Biosciences(NBIX.US)：2024年Q4财报实现营收6.277亿美元，前值为5.152亿美元，预期值为6.29亿美元；每股收益为1.69美元，前值为1.54美元，预期值为1.71美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/07051248003078.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["NBIX"],"gpt_icon":0},{"id":"2508567984","title":"大摩：维持Neurocrine Biosciences(NBIX.US)评级，由增持调整至增持评级, 目标价由170.00美元调整至185.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2508567984","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508567984?lang=zh_cn&edition=full","pubTime":"2025-02-04 21:11","pubTimestamp":1738674665,"startTime":"0","endTime":"0","summary":"大摩：维持Neurocrine Biosciences(NBIX.US)评级，由增持调整至增持评级, 目标价由170.00美元调整至185.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/04211147949362.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["NBIX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neurocrine.com","stockEarnings":[{"period":"1week","weight":0.0065},{"period":"1month","weight":0.0531},{"period":"3month","weight":-0.0776},{"period":"6month","weight":-0.1026},{"period":"1year","weight":0.1723},{"period":"ytd","weight":-0.0784}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.0161},{"period":"3month","weight":-0.0009},{"period":"6month","weight":0.0129},{"period":"1year","weight":0.1827},{"period":"ytd","weight":-0.0163}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Neurocrine Biosciences, Inc.于1992年1月在加利福尼亚州注册成立，并于1996年5月在特拉华州重新注册成立。该公司是一家专注于神经科学的生物制药公司，致力于发现、开发及商业化针对未充分解决的神经、精神、内分泌及免疫系统疾病的治疗方法。其产品组合涵盖美国食品药品监督管理局批准用于治疗迟发性运动障碍、亨廷顿病相关舞蹈病、经典先天性肾上腺皮质增生症、子宫内膜异位症及子宫肌瘤的疗法，并在核心治疗领域拥有从小分子到基因疗法的多元化在研管线。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.064262},{"month":2,"riseRate":0.3,"avgChangeRate":-0.015369},{"month":3,"riseRate":0.4,"avgChangeRate":-0.009054},{"month":4,"riseRate":0.344828,"avgChangeRate":-0.012555},{"month":5,"riseRate":0.586207,"avgChangeRate":0.048895},{"month":6,"riseRate":0.533333,"avgChangeRate":0.019493},{"month":7,"riseRate":0.5,"avgChangeRate":-0.001982},{"month":8,"riseRate":0.533333,"avgChangeRate":0.022782},{"month":9,"riseRate":0.566667,"avgChangeRate":0.02711},{"month":10,"riseRate":0.566667,"avgChangeRate":0.029718},{"month":11,"riseRate":0.6,"avgChangeRate":0.039502},{"month":12,"riseRate":0.633333,"avgChangeRate":0.040009}],"exchange":"NASDAQ","name":"神经分泌生物科学","nameEN":"Neurocrine Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"神经分泌生物科学(NBIX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供神经分泌生物科学(NBIX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"神经分泌生物科学,NBIX,神经分泌生物科学股票,神经分泌生物科学股票老虎,神经分泌生物科学股票老虎国际,神经分泌生物科学行情,神经分泌生物科学股票行情,神经分泌生物科学股价,神经分泌生物科学股市,神经分泌生物科学股票价格,神经分泌生物科学股票交易,神经分泌生物科学股票购买,神经分泌生物科学股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"神经分泌生物科学(NBIX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供神经分泌生物科学(NBIX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}